Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion Pharmaceuticals stock soars on NVIDIA investment in AI
11:41am, Wednesday, 12'th Jul 2023
Recursion Pharmaceuticals Inc shares surged 64% to $11.09 in late-morning trading on Wednesday after NVIDIA Corp announced it is making a $50 million investment to accelerate training of the biotech c
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom
08:43pm, Saturday, 08'th Jul 2023
AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery.
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
05:13am, Thursday, 29'th Jun 2023
Longevity efforts are forefront of the news cycle today, due in large part to recent coverage of tech billionaire Bryan Johnson's unique strategy to delay aging. This has investors trying to sniff out
Recursion (RXRX) Up on Completing REC-994 Study Enrollment
12:58pm, Wednesday, 14'th Jun 2023
Recursion's (RXRX) shares rise as it completes patient enrollment for a mid-stage study of REC-994 to treat cerebral cavernous malformations.
Recursion Pharmaceuticals: Unlocking The Future Of Biotech With AI-Powered Drug Discovery
12:21am, Wednesday, 14'th Jun 2023
Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like Astr
Recursion to Participate in Upcoming Investor Conferences
08:30am, Thursday, 01'st Jun 2023
SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the
Recursion Pharmaceuticals Is Going Big on AI. Here's Why It Could Be Worth Buying
08:45am, Monday, 29'th May 2023
Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients.
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
10:40am, Monday, 08'th May 2023
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago.
Recursion to Participate in Upcoming Investor Conferences
08:30am, Tuesday, 02'nd May 2023
Salt Lake City, May 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its p
Recursion to Participate in Upcoming Investor Conference
08:30am, Monday, 03'rd Apr 2023
Salt Lake City, April 03, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue Estimates
09:04pm, Monday, 27'th Feb 2023
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -106.67% and 79.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for th
Recursion to Participate in Upcoming Investor Conference
08:01am, Wednesday, 01'st Feb 2023
SALT LAKE CITY , Feb. 1, 2023 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation
Bears are Losing Control Over Recursion Pharmaceuticals (RXRX), Here's Why It's a 'Buy' Now
11:17am, Friday, 27'th Jan 2023
After losing some value lately, a hammer chart pattern has been formed for Recursion Pharmaceuticals (RXRX), indicating that the stock has found support. This, combined with an upward trend in earning
Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Wednesday, 25'th Jan 2023
Recursion Pharmaceuticals (RXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Recursion Pharmaceuticals (RXRX)? Wall Street Analysts Think 53.67%
11:18am, Wednesday, 25'th Jan 2023
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
